Up a level |
Journal Article
Horn, Leora, Rizvi, Naiyer, Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalman, Gerard, Wolf, Juergen, Paik, Paul, Zhu, Jin, Xu, Dong, Neely, Jaclyn, Qi, Zenhao, Harbison, Christopher T., Lynch, Mark and Ramalingam, Suresh S. (2015). LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC). Asia-Pac. J. Clin. Oncol., 11. S. 124 - 125. HOBOKEN: WILEY-BLACKWELL. ISSN 1743-7563
Horn, Leora, Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Paik, Paul, Li, Ang, Xu, Dong, Neely, Jaclyn, Qi, Zhenhao, Harbison, Christopher, Lynch, Mark and Ramalingam, Suresh S. (2015). Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. J. Thorac. Oncol., 10 (9). S. S175 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Mazieres, Julien, Zalcman, Gerard, Crino, Lucio, Biondani, Pamela, Barlesi, Fabrice, Filleron, Thomas, Dingemans, Anne-Marie C., Lena, Herve, Monnet, Isabelle, Rothschild, Sacha I., Cappuzzo, Federico, Besse, Benjamin ORCID: 0000-0001-5090-8189, Thiberville, Luc, Rouviere, Damien, Dziadziuszko, Rafal ORCID: 0000-0001-8080-9843, Smit, Egbert F., Wolf, Jurgen, Spirig, Christian, Pecuchet, Nicolas ORCID: 0000-0002-3321-5791, Leenders, Frauke, Heuckmann, Johannes M., Diebold, Joachim, Milia, Julie D., Thomas, Roman K. and Gautschi, Oliver (2015). Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J. Clin. Oncol., 33 (9). S. 992 - 1002. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Mazieres, Julien, Zalcman, Gerard, Crino, Lucio, Biondani, Pamela, Barlesi, Fabrice, Filleron, Thomas, Dingemans, Anne-Marie C., Lena, Herve, Monnet, Isabelle, Rothschild, Sacha I., Cappuzzo, Federico, Besse, Benjamin ORCID: 0000-0001-5090-8189, Thiberville, Luc, Rouviere, Damien, Dziadziuszko, Rafal ORCID: 0000-0001-8080-9843, Smit, Egbert F., Wolf, Jurgen, Spirig, Christian, Pecuchet, Nicolas ORCID: 0000-0002-3321-5791, Leenders, Frauke, Heuckmann, Johannes M., Diebold, Joachim, Milia, Julie D., Thomas, Roman K. and Gautschi, Oliver (2015). Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J. Clin. Oncol., 33 (9). S. 992 - 1002. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Mazieres, Julien, Zalcman, Gerard, Crino, Lucio, Biondani, Pamela, Besse, Benjamin ORCID: 0000-0001-5090-8189, Dingemans, Anne-Marie C., Lena, Herve, Monnet, Isabelle, Rothschild, Sacha ORCID: 0000-0003-1304-9340, Cappuzzo, Federico, Thiberville, Luc, Rouviere, Damien, Dziadziuszko, Rafal ORCID: 0000-0001-8080-9843, Smit, Egbert F., Wolf, Juergen, Spirig, Christian, Pecuchet, Nicolas, Diebold, Joachim, Milia, Julie and Gautschi, Oliver (2014). Efficacy of crizotinib in ROSI-rearranged lung cancer: The European experience. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Horn, Leora, Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M. ORCID: 0000-0001-7041-6368, Harbison, Christopher T., Baudelet, Christine, Lestini, Brian J. and Ramalingam, Suresh S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol., 16 (3). S. 257 - 266. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
Rizvi, Naiyer A., Mazieres, Julien, Planchard, David, Stinchcombe, Thomas E., Dy, Grace K., Antonia, Scott J., Horn, Leora, Lena, Herve, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A., Campos, Luis T., Gandara, David R., Levy, Benjamin P., Nair, Suresh G., Zalcman, Gerard, Wolf, Juergen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M. ORCID: 0000-0001-7041-6368, Harbison, Christopher T., Baudelet, Christine, Lestini, Brian J. and Ramalingam, Suresh S. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol., 16 (3). S. 257 - 266. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488